News | News By Subject | News by Disease News By Date | Search News

Lupus Nephritis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
JPM17: Aurinia (AUPH)’s CEO on a Mission to Improve the Way Lupus Nephritis is Treated     1/11/2017
Finding a Complementary Secondary Endpoint in Lupus Clinical Trials     1/10/2017
Aurinia (ISA.TO)'s Voclosporin Meets Primary Endpoint in Phase IIB Aura-LV Study in Lupus Nephritis     8/15/2016
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA     7/9/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact     3/19/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
23andMe is Sharing Users' Data Again, This Time With Pfizer (PFE)     1/15/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Primary Goal Not Met in Anthera Pharmaceuticals, Inc. (ANTH)'s Lupus Drug Study     6/28/2012
GlaxoSmithKline (GSK) Attacks National Institute for Clinical Excellence (NICE) for Rejecting New Lupus Treatment     4/27/2012
Big Human Genome Sciences, Inc. (HGSI) Lupus Drug Nears U.S. Market     3/8/2011
Human Genome Sciences, Inc. (HGSI) Seeks FDA Nod to Market Lupus Drug     6/10/2010
Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline (GSK) Announce Topline 76-Week Results of Phase 3 Trial of BENLYSTA in Systemic Lupus Erythematosus; Drug Fails Secondary Goals     4/20/2010
Human Genome Sciences, Inc. (HGSI) (JOBS), GlaxoSmithKline (GSK) Lupus Drug Works in 2nd Trial     11/2/2009

News from Around the Web
Lupus, Rheumatoid Arthritis May Raise Risk of Abnormal Heart Rhythm, University of Arkansas for Medical Sciences Study     5/9/2011
First Lupus Breakthrough in 50 Years, Monash University Study Reveals     5/6/2011
National Institutes of Health (NIH)'s Immune Cell's Role in Lupus Nephritis: Discovery Paves Way for Safety Testing of Potential New Use for Asthma Drug     6/3/2010
Lupus Patients at Risk for Olfactory Dysfunction, Chaim Sheba Medical Center Study     5/6/2009
'Multi-Target' Immune Therapy Improves Outcomes of Severe Lupus Nephritis in Nanjing University School of Medicine Study     7/2/2008
Overabundance of Immune Cells Might Trigger Lupus     2/15/2008
New Genetic Mutation That Halts The Development Of Lupus Discovered By Scripps Research Institute     1/21/2008
Gene Studies Home In On Lupus Cause     1/21/2008
New Approach for Attacking Lupus Identified     12/17/2007
Existing Drugs Show Promise for Treating End-Stage Renal Disease in Lupus     11/12/2007
UT Southwestern Medical Center: Preclinical Study Suggests Organ-Transplant Drug May Aid in Lupus Fight     8/16/2007
Research Links Genetic Mutations to Lupus, Wake Forest University Baptist Medical Center Study     7/30/2007
New Insights into Chronic Inflammation and Atherosclerosis     5/25/2007
Lupus Raises Pregnancy Death Risk: Study     11/13/2006
New Biomarkers For Lupus Found     11/10/2006

Press Releases
Aurinia (AUPH) Announces Development Plans For Voclosporin In Europe And Japan     4/7/2017
Despite 13 Reported Deaths in 2016, Aurinia (AUPH)'s Lupus Nephritis Drug Shows No New Safety Concerns     3/2/2017
Aurinia (AUPH) Selects Worldwide Clinical Trials As Its CRO For Phase 3 Lupus Nephritis Trial     1/27/2017
ImmuPharma plc (IMM.L) Release: Company Update On Lupuzor Pivotal Phase III Study Full Analysis Of Patient Recruitment     1/25/2017
Aurinia (ISA.TO) Confirms Receipt Of FDA End of Phase II Meeting Minutes     12/13/2016
Mallinckrodt (MNK) Release: Study Addresses Possible Impact Of H.P. Acthar Gel On Use Of Corticosteroids Among Patients With Rheumatoid Arthritis, Lupus, And Dermatomyositis/Polymyositis     11/18/2016
Aurinia (ISA.TO) Highlights Speed Of Remission From Global Phase IIb AURA Study Of Voclosporin In Lupus Nephritis At 2016 American College of Rheumatology Annual Meeting     11/16/2016
Aurinia (ISA.TO) Releases Open-Label AURION Data Demonstrating Increased Remission Rates Over Time For Voclosporin In The Treatment Of Lupus Nephritis     10/6/2016
Aurinia (ISA.TO) Announces That Voclosporin Achieves Primary And All Pre-Specified Secondary Endpoints In Its Phase IIb AURA-LV Study For Lupus Nephritis (LN)     9/30/2016
Lupus Research Alliance Announces Published Data Showing Effective Approach To Drug Repositioning     9/27/2016
XTL Biopharma (XTLB) Announces New Patent Filing In U.S. For Lupus Drug hCDR1     8/11/2016
Aurinia (ISA.TO) Announces 24 Week Remission Rates From The First Seven Patients In Its Open Label AURION Study In Lupus Nephritis (LN)     6/29/2016
Mallinckrodt (MNK) Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus     6/10/2016
Alliance for Children's Therapeutics (ACT) Presents Dalazatide Data Demonstrating Positive Response In Lupus     6/10/2016
NYU Langone Medical Center Release: Key Enzyme Keeps Antibodies From Targeting DNA And Driving Inflammation In Lupus     6/9/2016

//-->